Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Amgen Inc patents


Recent patent applications related to Amgen Inc. Amgen Inc is listed as an Agent/Assignee. Note: Amgen Inc may have other listings under different names/spellings. We're not affiliated with Amgen Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "A" | Amgen Inc-related inventors


 new patent  Drug cassette, autoinjector, and autoinjector system

A cassette for use with an injector has a housing, and a cassette identification arrangement (cassette ID) defining a code containing information about the cassette that is detectable and decipherable by an injector. The cassette may further have a sleeve movably disposed within the housing, for holding a drug container,... Amgen Inc

 new patent  Material and methods for treating or preventing her-3 associated diseases

Described herein are materials and methods for treating subjects having a HER-3 associated disease, by administering a first agent that binds to HER-3, in combination with a second agent that binds and/or inhibits another member of the HER family. The first and the second agent may be a biologic, such... Amgen Inc

Pharmaceutical formulations and methods of making the same

The invention relates to the formulation of pharmaceutical compositions of etanercept. The invention also relates to methods of removing buffer and of formulating pharmaceutical compositions of etanercept.... Amgen Inc

Dkk1 antibodies and methods of use

The present invention provides antibodies and immunologically functional fragments thereof that specifically bind DKK1 polypeptides. Methods for preparing such antibodies or fragments thereof as well as physiologically acceptable compositions containing the antibodies or fragments are also provided. Use of the antibodies and fragments to treat various diseases are also disclosed.... Amgen Inc

Anti-sclerostin antibodies and their use to treat bone disorders as part of a regimen

The invention relates to the treatment of bone disorders. In particular, the invention provides an approach involving administration of a high initial dose or doses of an sclerostin antibody to bring about a rapid increase in bone formation, followed by administration of lowers doses of the antibody to give a... Amgen Inc

Heterocyclic compounds and their uses

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE),... Amgen Inc

Homogeneous antibody populations

The present invention is generally directed to methods of producing an increase in the enrichment and/or recovery of preferred forms of monoclonal antibodies. More particularly, the invention relates to methods for eliminating disulfide heterogeneity in the hinge region of recombinant IgG2 antibody proteins.... Amgen Inc

Drug cassette, autoinjector, and autoinjector system

A cassette for use with an injector has a housing, and a cassette identification arrangement (cassette ID) defining a code containing information about the cassette that is detectable and decipherable by an injector. The cassette may further have a sleeve movably disposed within the housing, for holding a drug container,... Amgen Inc

Pediatric formulation

The present invention is directed to pediatric formulation of (R)-N-[-1-(1-naphthyl)-ethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine hydrochloride (hereinafter referred to as Cinacalcet HC1) and method of administering the same.... Amgen Inc

Processes of making and crystalline forms of a mdm2 inhibitor

The present invention provides processes for making 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates and processes for making the intermediates. Also provided are crystalline forms of the compound and the intermediates.... Amgen Inc

Human pac1 antibodies

Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of... Amgen Inc

Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture

Methods of modulating the properties of a cell culture expressing a protein of interest are provided. In various embodiments the methods relate to the addition of cell cycle inhibitors to growing cell cultures.... Amgen Inc

Immediate release formulations for oprozomib

This disclosure features immediate release pharmaceutical formulations (e.g., solid dosage forms, e.g., tablets) that are useful for the oral administration of oprozomib, or a pharmaceutically acceptable salt thereof, to a human or animal subject as well as methods of making and using the formulations.... Amgen Inc

Solution phase preparing etelcalcetide

The instant disclosure is directed to solution phase fragment coupling methods for preparing etelcalcetide and its pharmaceutically acceptable salts.... Amgen Inc

Growth differentiation factor 15 (gdf-15) constructs

Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels... Amgen Inc

Stable liquid formulation of amg 416 (etelcalcetide)

A liquid formulation comprising a peptide agonist of the calcium sensing receptor and method of preparing and using the formulation are provided.... Amgen Inc

Variant activin receptor

The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and... Amgen Inc

Bicyclic ketone sulfonamide compounds

as defined in the specification, an enantiomer, diastereomer, atropisomer thereof, or a mixture thereof, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders, cough,... Amgen Inc

Drug delivery device with vacuum assisted securement and/or feedback

A drug delivery device includes a housing with at least one pressure communication channel or aperture, which distributes a negative fluid pressure across its base to draw tissue against the device. The device can also include a porous, adhesive layer over the channel(s) or aperture(s), for attaching to tissue. The... Amgen Inc

Capture purification processes for proteins expressed in a non-mammalian system

Methods of purifying proteins expressed in non-mammalian expression systems in a non-native soluble form directly from cell lysate are disclosed. Methods of purifying proteins expressed in non-mammalian expression systems in a non-native limited solubility form directly from a refold solution are also disclosed. Resin regeneration methods are also provided.... Amgen Inc

Device and making aseptic connections

The present invention provides devices and methods for establishing aseptic connections between two or more components or subassemblies. The devices may be used in medical devices such as drug delivery pumps (10). In some embodiments, a connection is made between a drug container (50, 1050, 2050) and a fluid pathway... Amgen Inc

Variants of tissue inhibitor or metalloprotienase type three (timp-3), compositions and methods

The application concerns tissue inhibitor of metalloproteinase 3 (TIMP-3) muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them; in particular, muteins of TIMP-3 with specific amino acid substitutions in order to introduce N-linked glycosylation sites.... Amgen Inc

Methods of treatment using an interferon gamma inhibitor

The invention encompasses methods of treatment of interferon gamma (IFN-γ)-mediated diseases using IFN-γ inhibitors, such as anti-huIFN-γ antibodies, wherein levels of expression of one or more biomarkers are determined either before administration of the IFN-γ inhibitor and/or after administration. Also contemplated are methods of treatment using particular, pharmacodynamically effective doses... Amgen Inc

Drug delivery device with a rotatable drive mechanism

A rotatable drive mechanism for a drug delivery device may include a lead screw having a distal end, a proximal end, and external threads, a bearing, and a ball screw driver having a threaded aperture wherein the threaded aperture is configured to rotatably engage with the external threads of the... Amgen Inc

Method of treating or ameliorating type 1 diabetes using fgf21

Methods of treating metabolic diseases and disorders using a FGF21 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 1 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels, diabetic nephropathy, neuropathy, retinopathy, ischemic heart disease, peripheral vascular disease and cerebrovascular disease... Amgen Inc

Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease

Methods and pharmaceutical compositions are provided herein for the treatment of inflammatory disorders, in particular celiac disease, refractory celiac disease and non-celiac gluten sensitivity.... Amgen Inc

Antibody constructs for cdh19 and cd3

The present invention provides to a bispecific antibody construct comprising a first human binding domain which binds to human CDH19 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide... Amgen Inc

Methods for increasing mannose content of recombinant proteins

The present invention relates to methods of modulating the mannose content of recombinant proteins.... Amgen Inc

Self-buffering protein formulations

The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the... Amgen Inc

Drug delivery device with live button or user interface field

A drug delivery device includes a container for storing a drug, the container having a stopper for expelling the drug; an injection drive comprising an energy source for directly or indirectly acting on the stopper to expel the drug; a sensor for detecting contact between the drug delivery device and... Amgen Inc

Feed media

The invention provides stable feed media containing pyruvate and methods for stabilizing feed media by adding pyruvate. The invention further provides methods for producing proteins using such media and proteins produced through the use of such methods.... Amgen Inc

Stable frozen virus formulation

A live virus composition that maintains infectivity and provides improved virus stability during one or more freeze/thaw cycles and/or during long term storage in a liquid state at temperatures ranging from just above freezing to ambient temperatures.... Amgen Inc

Drug delivery device with proximity sensor

A drug delivery device, in the form of an injector, may include one of a number of systems for limiting the delivery of a medical fluid or drug product in case of movement of (e.g., removal of) the injector relative to the patient as determined by a proximity sensor. The... Amgen Inc

Process for manipulating the level of glycan content of a glycoprotein

The present invention provides a method for manipulating the fucosylated glycan content on a recombinant protein.... Amgen Inc

Production of glycoproteins using manganese

Culture media comprising manganese and methods of culturing cells to improve sialylation and glycosylation of glycoproteins are provided.... Amgen Inc

11/30/17 / #20170340746

Pegylated carfilzomib compounds

wherein R1, R2, linker, PEG, n and o are as defined herein. The invention also provides methods of making and using these compounds to treat cancer, and particularly to treat hematological malignancies including multiple myeloma.... Amgen Inc

11/30/17 / #20170342155

Methods and compositions relating to anti-ccr7 antigen binding proteins

The present invention provides compositions and methods relating to antigen binding proteins against CCR7, including antibodies, nucleic acids, vectors, methods of making the antigen binding proteins, and methods of using the antigen binding proteins.... Amgen Inc

11/23/17 / #20170333559

Reducing viscosity of pharmaceutical formulations

A method for reducing the viscosity of a pharmaceutical formulation is provided that utilizes a viscosity-reducing concentration of an excipient selected from the group consisting of the n-acetyl arginine, n-acetyl lysine, n-acetyl proline and mixtures thereof in combination with a therapeutiv protein. A stable pharmaceutical formulation is also provided.... Amgen Inc

11/09/17 / #20170320860

Heterocyclic triazole compounds as agonists of the apj receptor

where the definitions of the variables are provided herein.... Amgen Inc

11/02/17 / #20170313753

Methods of treating graft versus host disease using il-2 muteins

Described herein are immunosuppressive molecules including immunosuppressive variants of IL-2, and use of such molecules to treat inflammatory and autoimmune disorders.... Amgen Inc

10/26/17 / #20170306033

Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof

The present invention relates to bispecific antigen binding proteins that are capable of binding to both the human CGRP receptor and the human PAC1 receptor. Pharmaceutical compositions comprising the bispecific antigen binding proteins as well as methods for producing them are also disclosed. Methods of using the bispecific antigen binding... Amgen Inc

10/12/17 / #20170291929

Growth differentiation factor 15 (gdf-15) polypeptides

GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose... Amgen Inc

10/05/17 / #20170281625

Methods of treating heart failure

Methods of treating heart failure include administering to a subject having heart failure an effective amount of a triazole compound that is an agonist of the APJ receptor, a pharmaceutically acceptable salt of the compound, or a mixture thereof. Compounds particularly useful in such methods are provided herein.... Amgen Inc

10/05/17 / #20170281761

Method of treating alvelor bone loss through the use of anti-sclerostin antibodies

The invention provides a method of treating alveolar bone loss involving administration of a sclerostin inhibitor to a subject in need thereof.... Amgen Inc

09/28/17 / #20170275365

Alpha-4-beta-7 heterodimer specific antagonist antibody

There are disclosed alpha4beta7 heterodimer-specific antigen binding proteins, nucleic acids encoding them, and methods of making and using them.... Amgen Inc

09/28/17 / #20170275370

Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists

Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is... Amgen Inc

09/21/17 / #20170267673

Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use

wherein variables A4, A5, A6, A8, and each of Ra, Rb, R1, R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation... Amgen Inc

09/21/17 / #20170267769

St2 antigen binding proteins

Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are... Amgen Inc

09/21/17 / #20170267775

Cd27l antigen binding proteins

The present invention relates to CD27L antigen binding proteins, such an antibodies, polynucleotides encoding said CD27l antigen binding proteins, antibody drug conjugate compositions, and methods for diagnosing and treating diseases associated with CD27L expression.... Amgen Inc

09/07/17 / #20170253889

Promoter and regulatory elements for improved expression of heterologous genes in host cells

Disclosed are a recombinant expression vector and a host cell that contains the vector.... Amgen Inc

08/31/17 / #20170247451

Human pac1 antibodies

Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of... Amgen Inc

08/31/17 / #20170247476

Protease-activatable bispecific proteins

Described herein are protease-activatable proteins (PABPs), which, when activated, can mediate cytolysis of target cells by effector cells. Also provided are nucleic acids encoding such PABPs and methods of making and using PABPs.... Amgen Inc

08/17/17 / #20170233467

Antibodies directed to angiopoietin-1 and angiopoietin-2 for ocular therapies

The present disclosure provides methods of treating ocular disorders using anti-angiogenic antibodies and pharmaceutical formulations.... Amgen Inc

08/10/17 / #20170224934

Drug injection device with visual and audio indicators

A drug injection device (10) including a housing (12) for holding a container (20) having a needle (24) for penetrating skin and a plunger (42) for expelling a drug stored in the container. The device includes visual and/or audible indicators for indicating that the correct depth of needle penetration has... Amgen Inc

08/03/17 / #20170218062

Methods for treating crohn's disease using an anti-il23 antibody

The invention relates to products and methods for treating Crohn's disease. The products relate to antibodies that inhibit native human IL-23 while sparing IL-12. One example describes a Phase 1, randomized, double-blind, placebo-controlled, ascending multiple dose study to evaluate the safety, tolerability, pharmacokinctics and pharmacodynamics of an anti-IL-23 antibody (AMG... Amgen Inc

08/03/17 / #20170218077

Bcma and cd3 bispecific t cell engaging antibody constructs

The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to BCMA, a second domain binding to an extracellular epitope of the human and/or the Macaca CD3ε chain and a third domain, which is the specific Fc modality. Moreover, the invention... Amgen Inc

07/27/17 / #20170209571

Pharmaceutical composition comprising bispecific antibody constructs

The present invention provides novel and stable pharmaceutical compositions comprising bispecific single chain antibody constructs, cyclodextrins and a buffer.... Amgen Inc

07/27/17 / #20170209582

Protein formulations

The present disclosure provides solid protein formulations that are stable over a variety of temperatures for extended time periods. The present disclosure also provides methods of making and using these formulations.... Amgen Inc

07/27/17 / #20170210792

Antibody formulations

Described herein are anti-sclerostin antibody crystals, methods of making such antibody crystals and formulations comprising the antibody crystals.... Amgen Inc

07/20/17 / #20170202909

Formulated receptor polypeptides and related methods

Disclosed herein is an activin receptor IIB-based composition and related methods of use, e.g., to treat solid tumors. Also disclosed are methods of manufacturing the compound and formulation.... Amgen Inc

07/20/17 / #20170202909

Formulated receptor polypeptides and related methods

Disclosed herein is an activin receptor IIB-based composition and related methods of use, e.g., to treat solid tumors. Also disclosed are methods of manufacturing the compound and formulation.... Amgen Inc

07/13/17 / #20170198058

Crystalline antibody formulations

Described herein are anti-PCSK9 antibody crystals, methods of making such antibody crystals and formulations comprising the antibody crystals.... Amgen Inc

07/13/17 / #20170198059

Crystalline antibody formulations

Described herein are anti-PCSK9 antibody crystals, methods of making such antibody crystals and formulations comprising the antibody crystals.... Amgen Inc

07/06/17 / #20170190739

Method for preparing amg 416

A method for preparing AMG 416, or a pharmaceutically acceptable salt thereof, is provided. AMG 416 is a synthetic, eight amino-acid selective peptide agonist of the calcium sensing receptor. It is being developed as an intravenous treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients with chronic kidney disease—mineral and bone... Amgen Inc

07/06/17 / #20170190793

Carrier immunoglobulins

Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the... Amgen Inc

Patent Packs
06/29/17 / #20170182048

Cholesteryl ester transfer protein (cetp) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases

(hereinafter referred to as Compound A) for use in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, in particular hyperlipidemia or mixed dyslipidemia. A further aspect of the present invention relates to a pharmaceutical composition for use in the treatment of subjects suffering from... Amgen Inc

06/29/17 / #20170182253

Autoinjector with shock reducing elements

An injection device, method, and system for drug delivery includes a primary container for storing a drug, the container having a stopper movably disposed in the container for expelling the drug, an injection drive mechanism comprising a plunger for acting on the stopper and an energy source for exerting a... Amgen Inc

06/29/17 / #20170183391
06/29/17 / #20170183412

Human antigen binding proteins that bind to a complex comprising beta-klotho and an fgf receptor

The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing B-Klotho, and or FGF21-like mediated signaling. In embodiments, the antigen binding proteins specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. In... Amgen Inc

06/29/17 / #20170183417

Antibodies to opgl

Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.... Amgen Inc

06/29/17 / #20170182016

Biomarkers and use of met inhibitor for treatment of cancer

The present invention relates to methods of therapeutic treatment of cancer using selective tyrosine kinase inhibitors and cancer biomarkers, such as MET amplification and high Met expression for patient selection.... Amgen Inc

06/15/17 / #20170165373

Bcma antigen binding proteins

The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates.... Amgen Inc

06/15/17 / #20170166942

Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins

Methods of modulating the properties of a cell culture expressing a protein of interest are provided. In various embodiments the methods relate to the overexpression of proteins involved in the N-glycosylation pathway.... Amgen Inc

06/15/17 / #20170166654

Protein biomarker and uses thereof

The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at... Amgen Inc

06/15/17 / #20170166973

Nucleic acid biomarker and use thereof

The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at... Amgen Inc

06/08/17 / #20170157566

Process control use with filters and filtration processes

Systems and methods used to control tangential flow filtration are provided, including control systems and methods for use with connected systems with upstream processing units, such as chromatography processing units, in fluid communication with a tangential flow filtration processing unit. Also included are control systems and methods for performing continuous... Amgen Inc

06/01/17 / #20170151338

Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing

The present invention provides for improved compositions comprising a PEGsTNF-R1 which, in addition to having useful higher concentrations, demonstrate decreased viscosity (<400 cP) and improved stability.... Amgen Inc

05/25/17 / #20170143586

Vial adapter and system

A vial adapter includes a base having first and second opposing sides, a spike depending from the first side of the base, the spike having a spike passageway, and a connector disposed on the second side of the base, the connector having a connector passageway that is in fluid communication... Amgen Inc

05/25/17 / #20170144971

Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer

wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.... Amgen Inc

05/25/17 / #20170145049

Refolding proteins using a chemically controlled redox state

A method of refolding proteins expressed in non-mammalian cells present in concentrations of 2.0 g/L or higher is disclosed. The method comprises identifying the thiol pair ratio and the redox buffer strength to achieve conditions under which efficient folding at concentrations of 2.0 g/L or higher is achieved and can... Amgen Inc

Patent Packs
05/25/17 / #20170147787

System and detecting activation of a medical delivery device

Methods and systems for determining that a medical delivery device has been activated may be provided. According to certain aspects, a user captures a first image to determine if a medical delivery device is ready to be activated. The first image is transmitted to a health care provider which verifies... Amgen Inc

05/18/17 / #20170137485

Interleukin-2 muteins for the expansion of t-regulatory cells

Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also,... Amgen Inc

05/11/17 / #20170129961

Antibody constructs for cd70 and cd3

The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human CD70 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding... Amgen Inc

05/04/17 / #20170119969

Controllable drug delivery system and use

A drug delivery system is disclosed that includes a drug delivery device having a reservoir, a delivery cannula having a proximal end in fluid communication with the reservoir and a distal end to be received within a patient, and one or more controllable elements. The drug delivery system may further... Amgen Inc

05/04/17 / #20170122947

Risk-stratification of b-precursor acute lymphoblastic leukemia patients

The present invention relates to a method for risk-stratifying subjects suffering from B-precursor acute lymphoblastic leukemia (ALL), wherein said subjects are intended for a therapy comprising administration of a CD3 binding domain. Risk-stratification is based on the determination of the amount blast cells in a bone marrow sample from said... Amgen Inc

05/04/17 / #20170124284

Drug delivery system and use

A drug delivery system is disclosed that includes a drug delivery device having a reservoir and a delivery cannula having a proximal end in fluid communication with the reservoir and a distal end to be received within a patient. The drug delivery system may further include one or more sensors... Amgen Inc

05/04/17 / #20170124285

Devices and methods for assisting a user of a drug delivery device

Devices and methods are disclosed for assisting a user of a drug delivery device with an application executing on a mobile computing device. The mobile computing device may receive information from the drug delivery device related to its condition and/or operation and subsequently select an informational and/or instructional prompt to... Amgen Inc

04/27/17 / #20170114381

Methods for harvesting mammalian cell cultures

The invention provides methods and materials for culturing mammalian cells and harvesting recombinant protein.... Amgen Inc

04/20/17 / #20170106146

Autoinjector with low energy plunger loading

An injection device, method, and system for drug delivery includes a container for storing a drug, the container having a stopper movably disposed in the container for expelling the drug; an injection drive mechanism having a plunger for acting on the stopper and an energy source having a first selected... Amgen Inc

04/20/17 / #20170107255

Apelin polypeptides

The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.... Amgen Inc

04/20/17 / #20170107288

Dual receptor antagonistic antigen-binding proteins and uses thereof

This disclosure relates to antagonistic dual receptor antigen-binding proteins, e.g. antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases. The dual receptor antibodies may comprise an antibody to ActRII receptors and may be used to treat pathological condition. The pathological conditions can comprise muscle wasting... Amgen Inc

04/13/17 / #20170103186

Systems and methods for supporting patient use of a drug delivery device

Systems and methods are disclosed herein for supporting a patient's use of a drug delivery device. The patient may be associated with a support group via, for example, a social networking service for the purpose of increasing the likelihood that the patient will comply with a treatment regimen. Based on... Amgen Inc

04/06/17 / #20170095535

Use of leptin for treating human lipoatrophy and determining predisposition to said treatment

Leptin, leptin analogs, and leptin derivatives are used to treat patients with lipoatrophy. Leptin is effective against conditions of lipoatrophy for both genetic and acquired forms of the disease. A therapeutically effective amount of leptin can be administered in a variety of ways, including subcutaneously and using gene therapy methods.... Amgen Inc

04/06/17 / #20170098058

Systems and methods for remotely processing data collected by a drug delivery device

Systems and methods are disclosed for processing sensor data collected by a drug delivery device with an external computing device. The drug delivery device may include a reservoir and a delivery cannula having a proximal end in fluid communication with the reservoir and a distal end to be received within... Amgen Inc

03/30/17 / #20170088560

Compounds that inhibit mcl-1 protein

and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.... Amgen Inc

03/30/17 / #20170088620

Asgr inhibitors

Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing... Amgen Inc

03/30/17 / #20170088874

Methods for increasing mannose content of recombinant proteins

The present invention relates to methods of upregulating the high mannose glycoform content of a recombinant protein during a mammalian cell culture by manipulating the mannose to total hexose ratio in the cell culture media formulation.... Amgen Inc

03/23/17 / #20170081382

Interleukin-2 muteins for the expansion of t-regulatory cells

Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also,... Amgen Inc

03/23/17 / #20170081398

Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof

Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin 1 and/or angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.... Amgen Inc

03/23/17 / #20170081668

Method of modulating fibroblast accumulation or collagen deposition

The invention provides methods and compositions for reducing or preventing fibrosis in a subject suffering from a fibrotic disorder by administering a therapeutically effective amount of at least one antagonist to the cytokine thymic stromal lymphopoietin to the subject. In one embodiment, the methods and compositions further comprise administering at... Amgen Inc

03/23/17 / #20170082608

Assay for detecting th1 and th2 cell populations

The present disclosure relates to a method for detecting T helper cell or CTL subpopulations in a subject affected by disease or disorder having an immune component. The methods are also useful for determining efficacy of a treatment of the disease or disorder by detecting skewing of the T helper... Amgen Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Amgen Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Amgen Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###